Jaguar Health Licenses FDA-Approved Oral Mucositis Product for U.S. Market, Initiating Commercial Footprint in its Core Focus Area of Cancer Supportive Care
Accesswire
*Jaguar planning to begin commercial launch in Q3 2024 for Gelclair^®, the company's third prescription product*
*Oral..